Aurora Cannabis Inc. produces and distributes medical cannabis products globally. The company is headquartered in Edmonton, Canada.
| Revenue (TTM) | $314.07M |
| Gross Profit (TTM) | $138.74M |
| EBITDA | $-29.95M |
| Operating Margin | -12.90% |
| Return on Equity | -9.40% |
| Return on Assets | -3.72% |
| Revenue/Share (TTM) | $5.41 |
| Book Value | $5.93 |
| Price-to-Book | 0.87 |
| Price-to-Sales (TTM) | 1.06 |
| EV/Revenue | 1.223 |
| EV/EBITDA | 15.32 |
| Quarterly Earnings Growth (YoY) | -94.70% |
| Quarterly Revenue Growth (YoY) | -8.80% |
| Shares Outstanding | $63.31M |
| Float | $64.47M |
| % Insiders | 1.19% |
| % Institutions | 9.01% |
Volatility is currently expanding
Aurora Cannabis Inc. (ACB) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to earnings of $0.09 per share a year ago.
Aurora Cannabis shares surged after Organigram agreed to a C$561 million buyout, but competing bids, deal conditions and shareholder uncertainty remain.
EDMONTON, Alberta--(BUSINESS WIRE)--Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it will host an investor conference call on Thursday, November 12, 2026 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time to discuss its financial results for the second quarter 2027. The Company will report its financial results prior to market open that same morning. Investor Conference Call Details DA.
Aurora Cannabis heads into Q2 earnings with revenues expected to fall 20.1%, as market exits and reimbursement cuts weigh on results while international medical cannabis markets offer support.
NASDAQ | TSX: ACB Alberta Securities Commission dismisses Curaleaf's application concerning Aurora's ATM program. Curaleaf's unsuccessful application before the Alberta Securities Commission confirms Aurora's ATM program is compliant with Securities laws.
Curaleaf TodayCURLFCuraleaf$7.80 +0.17 (+2.26%) As of 02:38 PM Eastern52-Week Range$5.40▼$15.15Price Target$6.00Add to WatchlistCuraleaf Holdings, Inc. OTCMKTS: CURLF is aggressively maneuvering to absorb Aurora Cannabis Inc. NASDAQ: ACB, leveraging an estimated 217% ex-cash premium to force a shareholder reckoning and bypass an entrenched board.
NASDAQ | TSX: ACB Revised Hostile Bid continues to significantly undervalue Aurora; fails to address concerns previously raised by the Board. Aurora's Special Committee is actively exploring strategic alternatives to maximize value for Aurora shareholders.
A Q1 FY2027 revenue record from Tilray Brands (NASDAQ:TLRY) is drawing heavy selling, because the segment that built the company's following moved the wrong way. Tilray Brands shares are at $3.
NASDAQ | TSX: ACB Multi-million-dollar investment results in increased domestic production capacity in Germany, more than doubling expected annual flower output. Enhanced facility adopts Aurora's proven cultivation practices and proprietary genetics to support consistent, high-quality production.
Aurora's Special Committee will commence a thorough and independent review of the revised Hostile Bid and the Board will provide a formal recommendation to shareholders once the review is complete. Shareholders are advised to TAKE NO ACTION pending a formal recommendation.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ACB and any ticker you trade — then tracks every position and per-strategy win rate.
